Continued Antiretroviral Therapy With Abacavir, Amprenavir and Efavirenz
Status:
Completed
Trial end date:
2003-08-01
Target enrollment:
Participant gender:
Summary
This study will continue to treat and collect safety and efficacy data on patients who
participated in Glaxo-Wellcome's multi-center study on combination therapy with abacavir,
amprenavir and efavirenz (A Phase II Study Evaluating the Safety and Antiviral Activity of
Combination Therapy with 1592U89, 141W94 and DMP 266 (Sustiva) in HIV-1 Infected Subjects
with Detectable [greater than 400 Copies/mL] HIV-1 Plasma RNA Despite Treatment with a
Protease Inhibitor-Containing Regimen).
HIV-infected patients 18 years of age and older who participated in the above study at the
NIH site may be eligible for the current study. Participants will be followed every 3 months
with a general health evaluation and laboratory tests. This is a NIH study, and information
will not be provided to Glaxo Wellcome
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)